The knock on the company is going stale: this quarter's own facts cut against the standing doubt
The model's full reasoning — Q2 2022 call → NO我们根据要求,需要判断是否有一个明确的、公司特定的疑虑,并且本季度的运营证据是否明确反驳了该疑虑。 从电话会议中,我们看到分析师和公司管理层多次提到关于盈利能力、增长可持续性、客户扩张等。但我们需要找到一个具体的、反复出现的疑虑。 观察电话会议内容: - 管理层强调收入加速增长、客户增长、净留存率提高。 - 分析师提问中,有关于销售和营销效率、客户数量增长、大型企业部署等。 - 没有明显看到关于“亏损何时结束”的疑虑,因为管理层提到运营亏损但强调投资增长。 - 也没有关于依赖单一客户或市场的疑虑。 - 有一个问题关于“净增加客户数”的强劲,但那是正面的。 再仔细看,分析师Brent Bracelin问关于企业部署,但那是正面的。没有明显的负面疑虑。 或许疑虑是关于“增长可持续性”或“竞争”,但电话会议中管理层自信地谈论未来。 实际上,电话会议中管理层提到“我们正在经历最大的工作场所转型”,但那是背景。 也许疑虑是“公司能否盈利”,但管理层没有直接回应,而是说“长期来看,我们认为可以执行增长战略,并且毛利率和单位经济性将提供杠杆”。 但分析师没有直接问亏损问题。 另一个可能:关于“客户留存”或“扩张”,但那是正面的。 再读一遍,分析师Keith Weiss问关于客户数量增长,但那是正面的。 没有看到明显的公司特定疑虑。 因此,答案应为NO。 但让我们确认:是否有任何分析师或管理层提到“疑虑”?没有。 所以,答案是否定的。
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| CRGO | Freightos Limited | Q1 2024 | 2024-05-20 | C+ |
| IFS | Intercorp Financial Services Inc. | Q1 2024 | 2024-05-14 | C+ |
| PRA | ProAssurance Corporation | Q1 2024 | 2024-05-11 | D |
| LTRX | Lantronix, Inc. | Q3 2024 | 2024-04-29 | C |
| ASB | Associated Banc-Corp | Q1 2024 | 2024-04-25 | A |
| GL | Globe Life Inc. | Q1 2024 | 2024-04-23 | F |
| ASM | Avino Silver & Gold Mines Ltd. | Q4 2023 | 2024-03-21 | C+ |
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| GIII | G-III Apparel Group, Ltd. | Q4 2024 | 2024-03-14 | C |
| HP | Helmerich & Payne, Inc. | Q1 2024 | 2024-01-30 | C |
| PFE | Pfizer Inc. | Q4 2023 | 2024-01-30 | F |
| QTRX | Quanterix Corporation | Q3 2023 | 2023-11-07 | B |
| ALL | The Allstate Corporation | Q3 2023 | 2023-11-02 | C+ |
| DASH | DoorDash, Inc. | Q3 2023 | 2023-11-01 | C+ |
| PTN | Palatin Technologies, Inc. | Q4 2023 | 2023-09-29 | D |
| BZUN | Baozun Inc. | Q2 2023 | 2023-08-28 | D |
| GVP | GSE Systems, Inc. | Q1 2023 | 2023-05-15 | D |
| BXSL | Blackstone Secured Lending Fund | Q1 2023 | 2023-05-10 | A |
| FTHM | Fathom Holdings, Inc. | Q1 2023 | 2023-05-10 | C |
| SPIR | Spire Global, Inc. | Q1 2023 | 2023-05-10 | B |
| SBRA | Sabra Health Care REIT, Inc. | Q1 2023 | 2023-05-04 | B |
| BRX | Brixmor Property Group Inc. | Q1 2023 | 2023-05-02 | A |
| TACT | TransAct Technologies Incorporated | Q4 2022 | 2023-03-08 | A |
| VRE | Veris Residential, Inc. | Q4 2022 | 2023-02-22 | D |
| TOST | Toast, Inc. | Q4 2022 | 2023-02-16 | C+ |
| PKOH | Park-Ohio Holdings Corp. | Q3 2022 | 2022-11-13 | B |
| CLSD | Clearside Biomedical, Inc. | Q3 2022 | 2022-11-09 | C |
| SIBN | SI-BONE, Inc. | Q3 2022 | 2022-11-07 | C+ |
| CHE | Chemed Corporation | Q3 2022 | 2022-11-01 | B+ |
| YMM | Full Truck Alliance Co. Ltd. | Q2 2022 | 2022-08-25 | C+ |
| EXFY | Expensify, Inc. | Q2 2022 | 2022-08-12 | D |
| WD | Walker & Dunlop, Inc. | Q2 2022 | 2022-08-09 | C+ |
| DM | Desktop Metal, Inc. | Q2 2022 | 2022-08-08 | F |
| XHR | Xenia Hotels & Resorts, Inc. | Q2 2022 | 2022-08-05 | A |
| LIN | Linde plc | Q2 2022 | 2022-07-28 | B+ |
| CME | CME Group Inc. | Q2 2022 | 2022-07-27 | B |
| OGI | OrganiGram Holdings Inc. | Q3 2022 | 2022-07-14 | B+ |
| SE | Sea Limited | Q1 2022 | 2022-05-17 | F |
| VNRX | VolitionRx Limited | Q1 2022 | 2022-05-12 | F |
| OPK | OPKO Health, Inc. | Q1 2022 | 2022-05-09 | D |
| FARM | Farmer Bros. Co. | Q3 2022 | 2022-05-07 | D |
| BFIN | BankFinancial Corporation | Q1 2022 | 2022-05-06 | A |
| BXP | Boston Properties, Inc. | Q1 2022 | 2022-05-03 | A |
| STC | Stewart Information Services Corporation | Q1 2022 | 2022-04-29 | C+ |
| LOW | Lowe's Companies, Inc. | Q3 2021 | 2021-11-17 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| IPGP | IPG Photonics Corporation | Q3 2021 | 2021-11-02 | C |
| SXC | SunCoke Energy, Inc. | Q3 2021 | 2021-11-01 | A |
| EMR | Emerson Electric Co. | Q3 2021 | 2021-08-04 | B+ |
| EEX | Emerald Holding, Inc. | Q2 2021 | 2021-08-01 | C+ |
| GECC | Great Elm Capital Corporation | Q3 2018 | 2018-11-13 | B |
| UMH | UMH Properties, Inc. | Q3 2018 | 2018-11-02 | C+ |
| FOSL | Fossil Group, Inc. | Q1 2018 | 2018-05-08 | C |
| BCOV | Brightcove Inc. | Q1 2018 | 2018-04-26 | B+ |
| AVT | Avnet, Inc. | Q2 2018 | 2018-01-25 | B |
| PII | Polaris Inc. | Q3 2017 | 2017-10-24 | C+ |
| GNTX | Gentex Corporation | Q3 2017 | 2017-10-20 | B |
| MTG | MGIC Investment Corporation | Q3 2017 | 2017-10-18 | B+ |
| LIND | Lindblad Expeditions Holdings, Inc. | Q2 2017 | 2017-08-06 | C |
| BIIB | Biogen Inc. | Q2 2017 | 2017-07-25 | B |
| CAG | Conagra Brands, Inc. | Q2 2017 | 2016-12-22 | C+ |
| WYY | WidePoint Corporation | Q3 2016 | 2016-11-09 | D |
| ULBI | Ultralife Corporation | Q3 2016 | 2016-10-29 | C+ |
| ARAY | Accuray Incorporated | Q4 2016 | 2016-08-17 | B |
| GES | Guess?, Inc. | Q1 2017 | 2016-05-25 | F |
| RCL | Royal Caribbean Cruises Ltd. | Q1 2016 | 2016-04-29 | C+ |
| DD | DuPont de Nemours, Inc. | Q1 2016 | 2016-04-26 | B+ |
| HPP | Hudson Pacific Properties, Inc. | Q4 2015 | 2016-02-25 | C |
BRX · Q1 2023 → YESThe question asks if there's a standing company-specific doubt visible on the call, and if this period's operating evidence cuts against it. YES The standing doubt is the skepticism that tenant disruptions (especially bankruptcies like Bed Bath) will create occupancy pressure and throw markets out of equilibrium, given the recaptured space and potential for more filings. This is visible in analyst questions (Todd Thomas on Bed Bath impact and market equilibrium; others circling back on bad debt 75-110 bps and bankruptcy activity) and management's acknowledgment that "recent retailer bankruptcy announcements will result in occupancy pressure" while noting they've "been preparing for the last several quarters." This period's evidence cuts against it: record 94% total occupancy (up sequentially in a seasonally weak quarter), small-shop at 89.
CME · Q2 2022 → YESThe question is: Identify ONE well-defined DOUBT that has been weighing on the company, and see if the current period's operating evidence moves against that doubt. YES The standing doubt is the perceived risk that the legacy NEX Group businesses (BrokerTec and EBS) would continue to show range-bound revenue and fail to deliver meaningful growth despite a constructive macro backdrop, as directly raised by Alex Blostein. Management engages this concern head-on by recounting concrete operating evidence from 2Q: BrokerTec US treasuries ADV up 14% YoY, US repo up 25% YoY, EU repo up 14% YoY, plus $4.5 billion in new cross-sell volume from previously non-trading clients and record RV trading volumes of $2.4 billion; 90% of the migration to Globex is complete, with the remaining EBS migration also finished and system enhancements underway.
BXSL · Q1 2023 → YESThe question asks if there's a standing company-specific doubt visible in the transcript, and if this period's operating evidence moves against it. YES The standing doubt visible in the transcript is the skepticism that BXSL’s credit performance will be materially worse than the broader private-credit market because of its exposure to higher-rate environments and the “tails” of the portfolio (i.e., the small slice of companies whose interest-coverage ratios could fall below 1× when 5 % rates are stress-tested). Management itself flags this concern by noting that “it is less about averages… much more about the tails” and that investors keep asking about the percentage of the portfolio below 1× ICR. This quarter’s operating evidence directly counters that doubt: - 0.